HHS Sends Warning Letters to Drug Manufacturers Regarding 340B Practices

May 19, 2021

The US Department of Health and Human Services’ Health Resources and Services Administration (HRSA) on Monday sent letters to six major drug manufacturers, warning them that they could face steep fines if they don’t discount drug prices for pharmacies that contract with 340B providers. The letters were sent to AstraZeneca, Lilly USA, Novartis, Novo Nordisk, Sanofi and United Therapeutics. The letters follow an advisory opinion issued by HRSA in December.

The HHS actions follow letters from WSHA and other organizations and a lawsuit from 340B entities exhorting HHS to take action against drug manufacturers that were restricting or denying sales to 340B entities.(Andrew Busz, AndrewB@wsha.org)


Contact Us

Washington State Hospital Association
999 Third Avenue
Suite 1400
Seattle, WA 98104

Map / Directions

206.281.7211 phone
206.283.6122 fax


Staff List